Dr. Victor van Berkel of the University of Louisville stated his affirmative vote was hopeful rather than accurate, noting that the benefit of finding early-stage cancers with the test has not yet been proven.

From the articleFDA Panel Narrowly Backs Multi-Cancer Blood Test Despite Doubts It WorksAlso in FDA panel endorses first-of-a-kind cancer blood test from Grail